Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase

Journal of Medicinal Chemistry

Volumn 57, Issue 5, 2014, Pages 1902-1913

  Maynard, Andrew ^a   Crosby, Renae M ^a   Ellis, Byron ^a   Hamatake, Robert ^a   Hong, Zhi ^a   Johns, Brian A ^a   Kahler, Kirsten M ^a   Koble, Cecilia ^a   Leivers, Anna ^a   Leivers, Martin R ^a   Mathis, Amanda ^a,c   Peat, Andrew J ^a   Pouliot, Jeffrey J ^a   Roberts, Christopher D ^a   Samano, Vicente ^a   Schmidt, Rachel M ^a   Smith, Gary K ^a   Spaltenstein, Andrew ^a   Stewart, Eugene L ^a   Thommes, Pia ^b   Turner, Elizabeth M ^a   Voitenleitner, Christian ^a,d   Walker, Jill T ^a   Waitt, Greg ^a   Weatherhead, Jason ^a   Weaver, Kurt ^a   Williams, Shawn ^a   Wright, Lois ^a   Xiong, Zhiping Z ^a   Haigh, David ^b   Shotwell, J Brad ^a   more..

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GlaxoSmithKline Infectious Diseases Centre for Excellence for Drug Discovery ^*  (United States)

^d GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORONIC ACID DERIVATIVE; GSK 5852; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED RNA POLYMERASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENCY; DRUG SYNTHESIS; HEPATITIS C VIRUS; IN VITRO STUDY; MUTANT; NONHUMAN; PHARMACOPHORE; REPLICON; STRUCTURE ACTIVITY RELATION; WILD TYPE;

ANTIVIRAL AGENTS; BORONIC ACIDS; DRUG DISCOVERY; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HEPACIVIRUS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; RNA REPLICASE; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84896270278     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400317w     Document Type: Article

References (37)

1. Center for Drug Evaluation and Research. 2011 Novel New Drugs; Food and Drug Administration, US Department of Health and Human Services; http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm285554. htm (Accessed January 2012).
2. Bosdet, M. J. D.; Piers, W. E. B-N as a C-C Substitute in Aromatic Systems Can. J. Chem. 2009, 87, 8-29
3. Nielsen, F. H. Boron in Human and Animal Nutrition Plant Soil 1997, 193, 199-208
4. Hunter, P. Not Boring at All EMBO Rep. 2009, 10, 125-128
5. Ciani, L.; Ristori, S. Boron as a Platform for New Drug Design Expert Opin. Drug Discovery 2012, 7, 1017-1027
6. Zhdankin, V. V.; Persichini, P. J.; Zhang, L.; Fix, S.; Kiprof, P. Synthesis and Structure of Benzoboroxoles: Novel Organoboron Heterocycles Tetrahedron Lett. 1999, 40, 6705-6708
7. Rock, F. L.; Mao, W.; Yaremchuk, A.; Tukalo, M.; Crépin, T.; Zhou, H.; Zhang, Y.-K.; Hernandez, V.; Akama, T.; Baker, S. J.; Plattner, J. J.; Shapiro, L.; Martinis, S. A.; Benkovic, S. J.; Cusack, S.; Alley, M. R. K. An Antifungal Agent Inhibits an Aminoacyl-tRNA Synthetase by Trapping tRNA in the Editing Site Science 2007, 316, 1759-1761
8. a of the Benzoxaborole Pharmacophore ACS Med. Chem. Lett. 2012, 3, 48-52
9. Baker, S. J.; Tomsho, J. W.; Benkovic, S. J. Boron-containing inhibitors of synthetases Chem. Soc. Rev. 2011, 40, 4279-4285
10. Baker, S. J.; Zhang, Y.-K.; Akama, T.; Lau, A.; Zhou, H.; Hernandez, V.; Mao, W.; Alley, M. R. K.; Sanders, V.; Plattner, J. J. Discovery of a New Boron-containing Antifungal Agent, 5-Fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the Potential Treatment of Onychomycosis J. Med. Chem. 2006, 49, 4447-4450
11. Sutcliffe, J. A. Antibiotics in Development Targeting Protein Synthesis Ann. N. Y. Acad. Sci. 2011, 1241, 122-152
12. Smoum, R.; Rubinstein, A.; Dembitsky, V. M.; Srebnik, M. Boron Containing Compounds as Protease Inhibitors Chem. Rev. 2012, 112, 4156-4220
13. Li, X.; Zhang, S.; Zhang, Y.-K.; Liu, Y.; Ding, C. Z.; Zhou, Y.; Plattner, J. J.; Baker, S. J.; Bu, W.; Liu, L.; Kazmierski, W. M.; Duan, M.; Grimes, R. M.; Wright, L. L.; Smith, G. K.; Jarvest, R. L.; Ji, J.-J.; Cooper, J. P.; Tallant, M. D.; Crosby, R. M.; Creech, K.; Ni, Z.-J.; Zou, W.; Wright, J. Synthesis and SAR of Acyclic HCV NS3 Protease Inhibitors with Novel P4-Benzoxaborole Moieties Bioorg. Med. Chem. Lett. 2011, 21, 2048-2054
14. Priestley, E. S.; De Lucca, I.; Ghavimi, B.; Erickson-Viitanen, S.; Decicco, C. P. P1 Phenethyl Peptide Boronic Acid Inhibitors of HCV NS3 Protease Bioorg. Med. Chem. Lett. 2002, 12, 3199-3202
15. Kneteman, N. M.; Howe, A. Y. M.; Gao, T.; Lewis, J.; Pevear, D.; Lund, G.; Douglas, D.; Mercer, D. F.; Tyrrell, D. L. J.; Immermann, F.; Chaudhary, I.; Speth, J.; Villano, S. A.; O'Connell, J.; Collett, M. HCV796: A Selective Nonstructural Protein 5B Polymerase Inhibitor with Potent Anti-hepatitis C Virus Activity in Vitro, in Mice with Chimeric Human Livers, and in Humans Infected with Hepatitis C Virus Hepatology. 2009, 49, 745-752
16. O'Farrell, D.; Trowbridge, R.; Rowlands, D.; Jager, J. Substrate Complexes of Hepatitis C Virus RNA Polymerase (HC-J4): Structural Evidence for Nucleotide Import and de novo Initiation J. Mol. Biol. 2003, 326, 1025-1035
17. Luvino, D.; Baraguey, C.; Smietana, M.; Vasseur, J.. Borononucleotides: Synthesis, and Formation of a New Reversible Boronate Internucleosidic Linkage Chem. Commun. 2008, 2352-2354
18. Hang, J. Q.; Yang, Y.; Harris, S. F.; Leveque, V.; Whittington, H. J.; Rajyaguru, S.; Ao-leong, G.; McCown, M. F.; Wong, A.; Giannetti, A. M.; Le Pogam, S.; Talamas, F.; Cammack, N.; Najera, I.; Klumpp, K.. Slow Binding Inhibition and Mechanism of Resistance of Non-nucleoside Polymerase Inhibitors of Hepatitis C Virus J. Biol. Chem. 2009, 284 (23) 15517-15529
19. Feldstein, A.; Kleiner, D.; Kravetz, D.; Buck, M.. Severe Hepatocellular Injury With Apoptosis Induced by a Hepatitis C Polymerase Inhibitor J. Clin. Gastroenterol. 2009, 43 (4) 374-381
20. McCown, M. F.; Rajyaguru, S.; Kular, S.; Cammack, N.; Najera, I. GT-1A or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796 Antimicrob. Agents Chem. 2009, 53 (5) 2129-2132
21. Beaulieu, P. Non-nucleoside Inhibitors of the HCV NS5B Polymerase: Progress in the Discovery and Development of Novel Agents for the Treatment of HCV Infections Curr. Opin. Investig. Drugs. 2007, 8 (8) 614-634
22. Herlihy, K. J.; Graham, J. P.; Kumpf, R.; Patick, A. K.; Duggal, R.; Shi, S. T. Development of Intergenotypic Chimeric Replicons To Determine the Broad-Spectrum Antiviral Activities of Hepatitis C Virus Polymerase Inhibitors Antimicrob. Agents Chem. 2008, 52 (10) 3523-3531
23. Kim, A. Y.; Timm, J. Resistance Mechanisms in HCV: From Evolution to Intervention Expert Rev. Anti-Infect. Ther. 2008, 6 (4) 463-478
24. Sarrazin, C.; Zeuzem, S. Resistance to Direct Antiviral Agents in Patients with Hepatitis C Virus Infection Gastroenterology 2010, 138, 447-462
25. Wilfret, D.; Walker, J.; Voitenleitner, C.; Baptiste-Brown, S.; Lovern, M.; Kim, J.; Adkison, K.; Mathis, A.; Moss, L.; Yu, L.; Gan, J.; Spaltenstein, A. A Randomized, Double Blind, Dose Escalation, Fusion, First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single Doses of GSK5852 in Chronically Infected Hepatitis C Subjects. Unpublished results.
26. Shim, J.-H.; Larson, G.; Wu, J.- Z.; Hong, Z. Selection of 3′-Template Bases and Initiating Nucleotides by Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase J. Virology 2002, 76 (14) 7030-7039
27. Mosley, R. T.; Edwards, T. E.; Murakami, E.; Lam, A. M.; Grice, R. L.; Du, J.; Sofia, M. J.; Furman, P. A.; Otto, M. J. Structure of Hepatitis C Virus Polymerase in Complex with Primer-Template RNA J. Virol. 2012, 86 (12) 6503-6511
28. Reich, S.; Golbik, R. P.; Geissler, R.; Lilie, H.; Behrens, S.-E. Mechanism of Activity and Inhibition of the Hepatitis C Virus RNA-Dependent RNA Polymerase J. Biol. Chem. 2010, 285 (18) 13685-13693
29. Harrus, D.; Ahmed-El-Sayed, N.; Simister, S.; Miller, M.; Triconnet, M.; Hagedorn, C.; Mahias, K.; Rey, F.; Astier-Gin, T.; Bressanelli, S. Further Insights into the Roles of GTP and the C Terminus of the HCV Polymerase in Initiation of RNA Synthesis J. Biol. Chem. 2010, 285, 32906-32918
30. Gong, P.; Peersen, O. B. Structural Basis for the Active Site Closure by the Poliovirus RNA-Dependent RNA Polymerase Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 22505-22510
31. Sofia, M. J.; Chang, W.; Furman, P. A.; Mosley, R. T.; Ross, B. S. Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase J. Med. Chem. 2012, 55, 2481-2531
32. Nyanguile, O.; Devogelaere, B.; Vijgen, L.; Van den Broeck, W.; Pauwels, F.; Cummings, M. D.; De Bondt, H. L.; Vos, A. M.; Berke, J. M.; Lenz, O.; Vandercruyssen, G.; Vermeiren, K.; Mostmans, W.; Dehertogh, P.; Delouvroy, F.; Vendeville, S.; VanDyck, K.; Dockx, K.; Cleiren, E.; Raboisson, P.; Simmen, K. A.; Fanning, G. C. 1a/1b Subtype Profiling of Nonnucleoside Polymerase Inhibitors of Hepatitis C Virus J. Virol. 2010, 84 (6) 2923-2934
33. Voitenleitner, C.; Crosby, R.; Wang, A.; Walker, J.; Pouliot, J.; Woldu, E.; Van Horn, S.; Horton, J.; Creech, K.; Carballo, L.; You, S.; Remlinger, K.; Vamathevan, J.; Shotwell, J. B.; Spaltenstein, A.; Hong, Z.; Hamatake, R. Preclinical Characterization of GSK5852, a Novel HCV Polymerase Inhibitor. Unpublished results.
34. Johns, B. A.; Shotwell, J. B.; Haigh, D. Therapeutic Compounds. WO 2011/103063 A1, 2011.
35. Johns, B. A.; Shotwell, J. B.; Haigh, D. Compounds. WO 2012/067663 A1, 2012.
36. Molander, G. A.; Jean-Gerard, L. Scope of the Suzuki-Miyaura Cross-Coupling Reaction of Potassium Trifluoroboratoketohomoenolates J. Org. Chem. 2009, 74, 1297-1303
37. Molander, G. A.; Shin, I.; Jean-Gerard, L. Palladium-Catalyzed Suzuki-Miyaura Cross Coupling Reactions of Enantiomerically Enriched Potassium B -Trifluoroboratoamides with Various Aryl- and Hetaryl Chlorides Org. Lett. 2010, 12 (9) 4384-4387